These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Colorectal cancer AND CXCR4, D2S201E, 7852, ENSG00000121966, P61073, NPYY3R, NPY3R, HM89, NPYRL, LESTR, HSY3RR, LCR1, fusin, WHIM, NPYR, FB22, CD184 AND Clinical Outcome
7 results:

  • 1. A chemokine/chemokine receptor signature potentially predicts clinical outcome in colorectal cancer patients.
    Mitchell A; Hasanali SL; Morera DS; Baskar R; Wang X; Khan R; Talukder A; Li CS; Manoharan M; Jordan AR; Wang J; Bollag RJ; Singh N; Albo D; Ghosh S; Lokeshwar VB
    Cancer Biomark; 2019; 26(3):291-301. PubMed ID: 31524146
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Clinicopathologic and prognostic significance of immunohistochemical expression of HIF-1α, cxcr4 and CA9 in colorectal carcinoma.
    Saka B; Ekinci O; Dursun A; Akyurek N
    Pathol Res Pract; 2017 Jul; 213(7):783-792. PubMed ID: 28554753
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Prognostic significance of USP33 in advanced colorectal cancer patients: new insights into β-arrestin-dependent ERK signaling.
    Liu H; Zhang Q; Li K; Gong Z; Liu Z; Xu Y; Swaney MH; Xiao K; Chen Y
    Oncotarget; 2016 Dec; 7(49):81223-81240. PubMed ID: 27835898
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Ex-vivo characterization of circulating colon cancer cells distinguished in stem and differentiated subset provides useful biomarker for personalized metastatic risk assessment.
    Malara N; Trunzo V; Foresta U; Amodio N; De Vitis S; Roveda L; Fava M; Coluccio M; Macrì R; Di Vito A; Costa N; Mignogna C; Britti D; Palma E; Mollace V
    J Transl Med; 2016 May; 14(1):133. PubMed ID: 27176720
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. cxcr4/CXCL12 expression profile is associated with tumor microenvironment and clinical outcome of liver metastases of colorectal cancer.
    Sakai N; Yoshidome H; Shida T; Kimura F; Shimizu H; Ohtsuka M; Takeuchi D; Sakakibara M; Miyazaki M
    Clin Exp Metastasis; 2012 Feb; 29(2):101-10. PubMed ID: 22075627
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Circulating endothelial progenitors and cxcr4-positive circulating endothelial cells are predictive markers for bevacizumab.
    Matsusaka S; Mishima Y; Suenaga M; Terui Y; Kuniyoshi R; Mizunuma N; Hatake K
    Cancer; 2011 Sep; 117(17):4026-32. PubMed ID: 21858803
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Polymorphism and circulating levels of the chemokine CXCL12 in colorectal cancer patients.
    Dimberg J; Hugander A; Löfgren S; Wågsäter D
    Int J Mol Med; 2007 Jan; 19(1):11-5. PubMed ID: 17143542
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.